Description: <b>Flowering plant</b> uses ginger root for help with nausea, weight loss, arthritis, diabetes. Anti-inflammatory and antioxidant. <br>
Gingerol is a phenolic phytochemical compound found in fresh ginger that activates heat receptors on the tongue. It is normally found as a pungent yellow oil in the ginger rhizome.<br>
Ginger contains multiple bioactive compounds including 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, paradols, and zingerone.<br>
<pre>
In cancer-focused literature, the majority of mechanistic work centers on 6-gingerol and 6-shogaol.
Mechanistic themes (preclinical):
-Anti-inflammatory (NF-κB↓, COX-2↓)
-Survival pathway modulation (PI3K/AKT↓, STAT3↓ reported)
-MAPK modulation (ERK/JNK/p38 context-dependent)
-ROS modulation (antioxidant in normal cells; pro-oxidant at higher doses in tumor models)
-Cell-cycle arrest (G1 or G2/M reported)
-Apoptosis induction (mitochondrial pathway)
-Anti-angiogenic and anti-metastatic signaling (VEGF↓, MMPs↓ reported)
Bioavailability note:
-Gingerols are rapidly metabolized (glucuronidation/sulfation)
-Plasma levels after dietary intake are far below many in-vitro micromolar doses
-6-Shogaol is generally more potent than 6-gingerol in cell systems
</pre>
<p><b>Ginger / 6-Gingerol / 6-Shogaol</b> — Ginger is the rhizome of <i>Zingiber officinale</i> Roscoe and a botanical mixture containing pungent phenolic compounds, principally 6-gingerol in fresh ginger and increased proportions of 6-shogaol after drying or heating. It is formally classified as a medicinal food and botanical product; 6-gingerol and 6-shogaol are phenolic vanilloids, with 6-shogaol additionally functioning as an electrophilic Michael acceptor. Standard abbreviations include ginger, 6-G, 6-GIN, 6-SG and 6-SHO. Other constituents include 8-gingerol, 10-gingerol, paradols and zingerone. The anticancer evidence is predominantly preclinical and should not be equated with the established clinical use of ginger for nausea.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Electrophilic protein modification by 6-shogaol, including HSP60 destabilization and modulation of KEAP1 and other cysteine-sensitive proteins.</li>
<li>Suppression of NF-κB, COX-2, iNOS and inflammatory cytokine signaling.</li>
<li>Suppression of PI3K/AKT/mTOR and STAT3 survival signaling.</li>
<li>Mitochondrial dysfunction, oxidative stress and intrinsic caspase-dependent apoptosis in cancer cells.</li>
<li>Cell-cycle arrest through model-dependent modulation of cyclins, CDKs and checkpoint proteins.</li>
<li>Suppression of EMT, MMP activity, migration, invasion and angiogenic signaling.</li>
<li>NRF2-mediated cytoprotective and antioxidant signaling, particularly in normal or inflammatory tissue; this is context-dependent and may oppose oxidative cytotoxicity in some cancer settings.</li>
<li>Potential chemosensitization through disruption of survival signaling and stress-response proteins; evidence remains preclinical.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Gingerols and shogaols are absorbed orally but undergo extensive first-pass glucuronidation and sulfation. Circulating exposure consists predominantly of conjugated metabolites rather than free parent compounds. 6-Shogaol is generally more reactive and more potent than 6-gingerol in cell models, but it is chemically and metabolically unstable. Glucuronidation markedly reduces its cytotoxic and NRF2-modulating activity. Botanical preparations vary substantially according to cultivar, extraction method, storage, drying and heating.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer experiments use approximately 10–100 µM parent 6-gingerol or 6-shogaol. These concentrations generally exceed sustained free systemic exposure achievable through ordinary dietary ginger or conventional oral supplements. Colon and gastrointestinal tissues may receive greater local exposure to parent compounds and metabolites than distant tumors. The observed selectivity between malignant and normal cells remains model-dependent rather than clinically established.</p>
<p><b>Clinical evidence status:</b> Anticancer treatment evidence remains preclinical, consisting mainly of cell studies and animal xenograft models. Small randomized human studies have examined colorectal mucosal biomarkers, inflammatory eicosanoids and chemotherapy-induced nausea rather than tumor regression or survival. Results for chemotherapy-induced nausea are mixed, although some trials report improved quality of life or reduced acute symptoms when ginger is used adjunctively with standard antiemetics. Ginger is not an approved anticancer therapy, and purified 6-gingerol or 6-shogaol has not demonstrated clinical anticancer efficacy.</p>
<p><b>Safety / interaction constraints:</b> Food-level ginger is generally well tolerated; concentrated supplements can cause gastrointestinal discomfort or heartburn. Platelet inhibition and clinically relevant bleeding interactions remain incompletely defined, but caution is appropriate with warfarin, direct oral anticoagulants, antiplatelet drugs, bleeding disorders and surgery. Product standardization is important because dried or thermally processed ginger may contain substantially more 6-shogaol than fresh ginger.</p>
<h3>Gingerol and Shogaol Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Electrophilic protein targeting and HSP60 stability</td>
<td>HSP60 stability ↓; proteasomal degradation ↑; mitochondrial function ↓</td>
<td>Electrophile-responsive proteins modulated (context-dependent)</td>
<td>P, R</td>
<td>Proteotoxic and mitochondrial stress</td>
<td>Most directly demonstrated for 6-shogaol. Its α,β-unsaturated carbonyl can react with protein cysteines; this mechanism should not automatically be assigned to non-electrophilic ginger constituents.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory transcription</td>
<td>IKK activity ↓; NF-κB activation ↓; COX-2 ↓; iNOS ↓; TNF-α and IL-6 ↓</td>
<td>Inflammatory signaling ↓; endothelial activation ↓</td>
<td>R, G</td>
<td>Anti-inflammatory and anti-survival signaling</td>
<td>A recurring effect of ginger extracts, gingerols and 6-shogaol, although potency and direct molecular targets differ among preparations.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT mTOR survival axis</td>
<td>PI3K ↓; AKT phosphorylation ↓; mTOR signaling ↓</td>
<td>AKT may be preserved or ↑ during tissue protection (context-dependent)</td>
<td>R, G</td>
<td>Growth suppression and apoptosis sensitization</td>
<td>Direction differs by biological context. Suppression is reported in cancer models, whereas activation can contribute to protection from ischemic or inflammatory injury.</td>
</tr>
<tr>
<td>4</td>
<td>STAT3 survival transcription</td>
<td>STAT3 phosphorylation ↓; nuclear signaling ↓; survival proteins ↓</td>
<td>↔ (model-dependent)</td>
<td>R, G</td>
<td>Proliferation and survival suppression</td>
<td>6-Shogaol has inhibited constitutive and inducible STAT3 signaling in several tumor models.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial apoptosis</td>
<td>Mitochondrial membrane potential ↓; Bax/Bcl-2 ratio ↑; cytochrome c release ↑; caspase-9 and caspase-3 ↑; PARP cleavage ↑</td>
<td>Apoptosis ↓ during some injury models (context-dependent)</td>
<td>R, G</td>
<td>Intrinsic apoptosis</td>
<td>Often downstream of HSP60 destabilization, oxidative stress and AKT or STAT3 suppression.</td>
</tr>
<tr>
<td>6</td>
<td>ROS and redox stress</td>
<td>ROS ↑ at cytotoxic concentrations; oxidative damage ↑; apoptosis ↑ (dose-dependent)</td>
<td>ROS ↓; antioxidant defenses ↑</td>
<td>P, R</td>
<td>Biphasic redox modulation</td>
<td>Pro-oxidant cancer effects generally occur at micromolar concentrations. Antioxidant and cytoprotective effects predominate in many normal-cell and inflammatory models.</td>
</tr>
<tr>
<td>7</td>
<td>KEAP1 NRF2 antioxidant response</td>
<td>NRF2 ↑ (context-dependent); possible cytoprotection or treatment resistance</td>
<td>NRF2 ↑; HO-1 ↑; NQO1 ↑; glutathione-related enzymes ↑</td>
<td>R, G</td>
<td>Secondary cytoprotective response</td>
<td>6-Shogaol can modify cysteine-sensitive NRF2 regulatory mechanisms. NRF2 activation is protective in normal tissue but may be undesirable in NRF2-dependent tumors.</td>
</tr>
<tr>
<td>8</td>
<td>MAPK stress signaling</td>
<td>JNK and p38 modulation; ERK ↓ or transiently ↑ (context-dependent)</td>
<td>Stress-MAPK activation ↓ or adaptive signaling ↑ (context-dependent)</td>
<td>P, R</td>
<td>Stress signaling and inflammatory regulation</td>
<td>MAPK direction varies by compound, dose, cell type and sampling time; it should not be represented as uniformly activated or inhibited.</td>
</tr>
<tr>
<td>9</td>
<td>Cell-cycle checkpoints</td>
<td>G1 or G2/M arrest ↑; cyclin D1 ↓; cyclin B1 and CDK modulation</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>The arrested phase is tumor-model dependent and may differ between 6-gingerol, 6-shogaol and whole-ginger extracts.</td>
</tr>
<tr>
<td>10</td>
<td>EMT migration and matrix degradation</td>
<td>Snail ↓; N-cadherin ↓; MMP-2 and MMP-9 ↓; migration and invasion ↓</td>
<td>Endothelial and leukocyte migration ↓ during inflammation</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Frequently linked to inhibition of IKK, NF-κB, STAT3 and AKT signaling.</td>
</tr>
<tr>
<td>11</td>
<td>Angiogenic signaling</td>
<td>VEGF expression ↓; endothelial recruitment and tube formation ↓</td>
<td>Inflammation-associated angiogenesis ↓</td>
<td>G</td>
<td>Anti-angiogenic activity</td>
<td>Evidence is preclinical and includes direct endothelial effects; impaired physiological angiogenesis is a theoretical context-dependent concern.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>Taxane, platinum or other drug response ↑ (model-dependent)</td>
<td>Normal-tissue toxicity may ↓ in selected models (model-dependent)</td>
<td>G</td>
<td>Adjunctive treatment sensitization</td>
<td>Reported mechanisms include HSP60 destabilization and suppression of AKT, mTOR, STAT3 and NF-κB. No clinical sensitization benefit has been established.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Free parent exposure low; rapid conjugation; botanical composition heterogeneous</td>
<td>Bleeding interaction and gastrointestinal tolerability require consideration</td>
<td>—</td>
<td>Exposure and evidence limitation</td>
<td>Most cytotoxic experiments use free parent concentrations substantially above sustained human plasma exposure. Existing human trials primarily address nausea or biomarkers rather than cancer treatment efficacy.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>